干扰素基因刺激剂
刺
免疫系统
免疫疗法
癌症免疫疗法
医学
鸟苷
封锁
免疫检查点
药理学
癌症
先天免疫系统
调解人
免疫学
生物
内科学
受体
生物化学
航空航天工程
工程类
作者
Jianping Wang,Fanfei Meng,Yoon Yeo
标识
DOI:10.1016/j.copbio.2024.103105
摘要
Agonists of the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-Stimulator of Interferon Genes (STING) pathway, a critical mediator of innate immune response to foreign invaders with DNA, have gained significant interest in cancer immunotherapy. STING agonists are envisioned as a way of complementing the antitumor activity of the patient's immune system and immune checkpoint blockade therapy. However, their clinical development has been challenging due to the poor pharmacokinetic and physicochemical properties. This review discusses drug delivery efforts to circumvent the challenges, their accomplishment, and unmet needs based on the last five years of literature.
科研通智能强力驱动
Strongly Powered by AbleSci AI